MIDAS SHARE TIPS: Medical group MaxCyte, has its finger on the pulse
It was floated on London's junior market in 2016 at 70p a share. The stock shot up to more than £3 by April 2017, but has since drifted down to £1.61. This is unjustified and the shares should rebound.